Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab has been studied in metastatic colon cancer.
Purity:
>95%
CAS Number:
[1024603-92-6]
Target:
VEGFR
T76866
T76866
* VAT and and shipping costs not included. Errors and price changes excepted